Wilson B E, Hamilton E C
Division of Endocrinology, University of Nevada School of Medicine, Las Vegas 89102, USA.
J Endocrinol Invest. 1996 Jan;19(1):54-8. doi: 10.1007/BF03347859.
Thyrotoxicosis rarely precipitates heart failure. Older patients and those with underlying cardiac disease are at greater risk of experiencing this complication of thyrotoxicosis. A 43 year old male who presented with subclinical thyrotoxicosis, atrial fibrillation, and a dilated cardiomyopathy is discussed. There was no evidence of clinically significant underlying cardiac disease. At admission, the patient had an ejection fraction of 25%. Thyrotoxicosis was treated with propylthiouracil. At 14 weeks after hospitalization, the patient had an ejection fraction of 50% with significant reduction in cardiac chamber sizes and left ventricular mass index. He was biochemically euthyroid at that time. After ten months of propylthiouracil therapy, he had progressive improvement in cardiac function and decrease in left ventricular mass index. Thyrotoxicosis-associated cardiomyopathy may reverse significantly with treatment of thyrotoxicosis alone; this complication of thyrotoxicosis should be considered in any young individual with a dilated cardiomyopathy of unknown etiology.
甲状腺毒症很少引发心力衰竭。老年患者以及患有基础心脏疾病的患者发生甲状腺毒症这一并发症的风险更高。本文讨论了一名43岁男性,他表现为亚临床甲状腺毒症、心房颤动和扩张型心肌病。没有证据表明存在具有临床意义的基础心脏疾病。入院时,患者的射血分数为25%。甲状腺毒症采用丙硫氧嘧啶治疗。住院14周后,患者的射血分数为50%,心腔大小和左心室质量指数显著降低。当时他的生化指标显示甲状腺功能正常。经过十个月的丙硫氧嘧啶治疗,他的心脏功能逐渐改善,左心室质量指数下降。仅通过治疗甲状腺毒症,甲状腺毒症相关的心肌病可能会显著逆转;对于任何病因不明的扩张型心肌病年轻个体,都应考虑甲状腺毒症的这一并发症。